Vol 22, No 2 (2017)
Review paper
Published online: 2017-03-01

open access

Page views 283
Article views/downloads 309
Get Citation

Connect on Social Media

Connect on Social Media

Dose to organ at risk and dose prescription in liver SBRT

Rives Michel1, Izar Françoise1, Parent Laure1, Modesto Anouchka1, Portier Guillaume2, Kirzin Sylvain2
DOI: 10.1016/j.rpor.2017.03.001
Rep Pract Oncol Radiother 2017;22(2):96-102.

Abstract

Stereotactic body radiation therapy (SBRT) is delivered in a curative intent to many primary and secondary tumors.

Concerning liver metastasis, SBRT can be safely delivered using one to five fractions. An excellent local control is obtained with doses from 20 to 60[[ce:hsp sp="0.25"/]]Gy. For primary hepatic tumors, results are also good, but the risk of hepatic toxicity related to liver pre-existent pathology must be taken into account. Radiation induced liver disease (RILD) is not frequent in its classical presentation, but modifications of liver enzymes are often observed. Other toxicities of SBRT on the duodenum, small bowel and biliary tract are also described. With respect to contraindications and dose limitations on surrounding structures, SBRT is well tolerated and takes place among curative treatment of liver tumors, as surgery, radiofrequency and embolization.

Article available in PDF format

View PDF Download PDF file



Reports of Practical Oncology and Radiotherapy